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Resistance to thyroid  hormone (RTH) is  a syndrome characterized by  reduced sensitivity  to the thyroid hormone. It 
is generally caused by mutations in the thyroid hormone receptor β (TRβ) gene. On the basis of its clinical features, 
two different forms of this syndrome have been described: generalized resistance and pituitary resistance. A total of 122 
TRβ gene mutations have been identified thus far. A 38-year-old woman presented with intermittent palpitation. Thyroid 
function  tests  revealed  elevated  levels  of  free  T4  and  TSH.  TSH  α-subunit  levels  were  0.41  mIU/mL,  and  magnetic 
resonance images of the sellar region evidenced no abnormal findings. The TSH response to TRH stimulation was found 
to be normal. The sequence analysis of the TRβ gene verified a missense mutation in exon 11, and the observed amino 
acid alteration was a substitution of a valine for a methionine at codon 349. We report the first case of a woman with RTH, 
which  was  found  to  be  caused  by  a m i s s e n s e  m u t a t i o n  ( V 3 4 9 M )  i n  the  TRβ  gene.
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INTRODUCTION
Thyroid  hormone  resistance  (RTH)  syndrome  is  a  rare 
disorder,  which  is  characterized  by  reduced  target  tissue 
responsiveness  to  circulating  free-thyroid  hormones.  Thyroid 
hormone  resistance  was  initially  described  by  Refetoff  et  al.  in 
1967
1). Typically, patients evidence elevated serum levels of free 
T4 and T 3 associated with normal or slightly elevated TSH
2). On 
the  basis of  the  clinical  features,  at  least  two  different  forms  of 
RTH  have  been  described:  generalized  resistance  to  thyroid 
hormone (GRTH), in which patients are asymptomatic with a few 
clinical signs, and pituitary resistance to thyroid hormone (PRTH), 
in  which  patients  present  with  some  thyrotoxicosis-  associated 
s i g n s  a n d  s y m p t o m s .  H o w e v e r ,  t h e r e  i s  a  w i d e  o v e r l a p  i n  t h e  
s y m p t o m s  a n d  s i g n s  e v i d e n c e d  b y  i n d i v i d u a l s  w i t h  G R T H  a n d  
PRTH
3).  Although  the  clinical  expression  of  this  syndrome  is 
heterogenous,  goiter is  the  most  common  clinical  finding  which 
brings  the  individual  to  medical  attention
3),  and  the  classic 
features  include  attention-deficit  hyperactivity  disorder,  delays  in 
growth,  and  tachycardia
1).  R e s i s t a n c e  t o  t h y r o i d  h o r m o n e  i s  
generally  transmitted  in  an  autosomal  dominant  manner. 
However,  sporadic  de  novo  cases  are  also  common,  although 
recessive inheritance is rare
1). The linkage between RTH and the 
TRβ  gene  was  elucidated  in  1988
4).  Since  that  time, 
approximately  100  mutations  have  been  detected  in  this  gene
1,
5),  which  are  clustered  primarily  in  hot  spots i n  t h e  T 3-binding 
domain (exons 8, 9 and 10)
6-8). In this study, we report the first 
case  in  Korea  of  a  woman  with  PRTH  caused  by  a  missense 
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D a i l y  d r u g  d o s e  a n d  
duration  of  administraion
fT4
(0.7-1.8  ng/dL)
T3
(80-200  ng/dL)
TSH
(0.1-4.2  μIU/mL)
2005/1
2005/5  (methiamazole  10  mg    for  8  weeks)
2005/8
2005/11  (atenolol  100  mg  for  4  weeks)
2.51
1.89
3.53
3.76
163
224
300
250
14.24
33.59
3.0
1.9
Table  1.  Hormonal  parameters  in  a  women  with  resistance  to  thyroid  hormone 
Basal 30  min 60  min 90  min 120  min
TSH  (μIU/mL  ) 2.3 30.8 19.0 12.6 7.6
Table  2.  Thyroid-stimulating  hormone  (TSH)  response  to  Thyrotropin-release  hormone  (TRH)  200  μg  stimulation 
Figure  1. 
99mTechnetium  thyroid  scan  reveals  diffuse  enlargement  of  both  thyroid  glands  without 
abnormal  focal  lesions.
CASE REPORT
A  38-year-old  Korean  woman  was  referred  to  us  in  June 
1998,  complaining  of  intermittent  palpitation  that  had  persisted 
for  2  years.  Her  treatment  was  initiated  under  the  diagnosis  of 
hyperthyroidism in June 1996 at a primary care clinic, and after 
a  six-month  treatment,  she  discontinued  medication.  When  first 
seen at our clinic, she weighed 53 kg, her height was 158 cm, 
her blood pressure was 130/80 mmHg, and her pulse rate was 
9 0  b e a t s / m i n .  T h e  p a t i e n t  h a d  n o  f a m i l y  h i s t o r y  o f  t h y r o i d  
diseases. The patient's thyroid gland was diffusely symmetrically 
enlarged, and no thrill, bruit, or exophthalmos was detected. At 
that time, her thyroid function tests revealed free T4, 2.60 ng/dL 
(range,  0.7-1.8);  T3,  1 5 0  n g / d L  ( r a n g e ,  8 0 - 2 0 0 ) ;  T S H ,  3 . 0  μ
IU/mL  (range,  0.1-4.2);  anti-thyroglobulin  (TG)  antibody,  20.34 
U/mL  (<0.3);  and  anti-microsomal  antibody,  11.30  U/mL  (<0.3).
After  three  visits,  the  patient  was  lost  to  follow-up.  In 
December  2004,  she  visited  a  primary  care  clinic,  and  her 
thyroid  function  tests  revealed  free  T4,  2.51  ng/dL;  T3,  163 
ng/dL; and TSH 14.24 μIU/mL. In February 2005 she received 
an  anti-thyroid  drug,  methimazole  10  mg,  due  to  suspicion  of 
d i f f u s e  g o i t e r .  S h e  w a s  a g a i n  r e f e r r e d  t o  u s  i n  J u l y  2 0 0 5  f o r  
f u r t h e r  e v a l u a t i o n  a n d  t r e a t m e n t  f o r  d i f f u s e  g o i t e r .  T h y r o i d  
function tests, which were conducted at a primary care clinic in 
March  2005,  revealed  free  T4,  1.89  ng/dL;  T3,  224  ng/dL;  and 
TSH,  33.59  μIU/mL.  We  then  discontinued  methimazole,  and 
the  patient  was  scheduled  to  take  thyroid  function  tests  after 
one  month.  Thyroid  function  tests  were  conducted  one  month 
later,  and  revealed  the  following:  free  T4,  3.53  ng/dL;  T3,  300 
ng/dL;  TSH,  3.0  μIU/mL;  and  thyroxine-binding  globulin  (TBG), 
23.08  μg/mL  (range,  11.3-28.9).  Tests  for  thyroid  auto- 
antibodies  revealed  TG  antibody,  68.04  U/mL;  anti-microsomal 
antibody, >100 U/mL; thyroid stimulating immunoglobin (TSI), 0% 
( < 1 5 ) ;  a n d  T 3 a n d  T 4  autoantibodies,  negative.  Thereafter,  the 
patient  was  treated  with  atenolol  100  mg  for  4  weeks.  Four 
weeks  later,  she  had  no  palpitation  and  her  medication  was 
discontinued. Thyroid scans indicated that the thyroid gland was 
diffusely  enlarged,  but  we  noted  no  abnormal  focal  lesions 
(Figure  1).  Basal  serum  TSH  levels  were  abnormally  high,  and 
increased  to  a  significant  degree  after  stimulation  with  200  μg 
of  TRH  (Table  1).  The  level  of  TSH  -subunit  was  0.41  mIU/mL 
(range,  0-0.9),  TSH  α-subunit/TSH  was  1,  and  sex  hormone- Ji  Yon  Kim,  et  al  :  Resistance  to  Thyroid  Hormone  and  Missense  Mutation 47
Figure  2.  S e l l a r  M R I  s h o w s  n o r m a l  p i t u i t a r y  g l a n d s .
binding globulin (SHBG) was 39.23 nmol/L (range, 30-100). MR 
imaging  of  the  sellar  lesion  evidenced  no  abnormal  findings 
(Figure  2).  For  the  next  diagnostic  plan,  we  conducted  a 
sequence  analysis  of  the  TRβ  gene.  The  result  revealed  a 
missense  mutation  in  exon  11  and  an  amino  acid  alterationn-
amely,  a  substitution  of  valine  for  methonine  at  codon  349 
(Figure  3).  On  the  basis  of  these  results,  she  was  ultimately 
diagnosed  with  thyroid  hormone  resistance  syndrome,  and  she 
has  been  followed  up  with  periodic  thyroid  function  tests. 
DISCUSSION
Thyroid  hormone  resistance  syndrome  is  characterized  by 
elevated levels of circulating free thyroid hormone, inappropriate 
TSH  secretion,  and  reduced  peripheral  tissue  responses  to  the 
activity of iodothyronine. Inappropriate secretion of TSH and the 
coexistence  of  elevated  serum  thyroid  hormone  and  normal  TSH 
levels  has  been  noted  in  several  situations,  including  abnormal 
thyroid hormone transport, TSH-secreting pituitary neoplasms, and 
pituitary  or  peripheral  resistance  to  thyroid  hormones
9, 10).
RTH  is  the  consequence  of  mutations  in  the  gene  of  the 
thyroid  hormone  receptor  (TRs).  The  mutant  TR  interferes  with 
the  activity  of  normal  TR  to  induce  the  clinical  syndrome
11).  As 
RTH  patients  present  with  elevated  thyroid  hormone  levels  and 
goiter,  frequently  accompanied  by  some  manifestations  of 
thyrotoxicosis,  the  condition  is  often  misdiagnosed  as  Graves' 
disease. However, exophthalmos has never been identified as a 
feature of RTH, and thyroid auto-antibodies have been detected 
only  in  approximately  4%  of  patients
12).  By  way  of  contrast, 
thyroid  hormone  hypersecretion  as  the  result  of  stimulating 
auto-antibodies  (Graves'  disease)  or  hyperfunctioning  thyroid 
tissue  (autonomous  single  or  multinodular  goiter)  is  uniformly 
associated  with  the  inhibition  of  TSH  secretion,  resulting  in 
unmeasurable  serum  TSH  levels
13). 
Clinically, thyroid hormone resistance can be divided into two 
entities:  GRTH  and  PRTH
11).  B o t h  G R T H  a n d  P R T H  a r e  r a r e  
diseases, occurring at  any age and with no sex predilection.  In 
general, diagnoses of PRTH are made largely on the basis of the 
presence  of  the  clinical  signs  and  symptoms  of  hyperthy-
roidism
13). Comprehensive assessments utilizing biochemical and 
physiological  indices  of  thyroid  hormone  action  are  useful,  but 
are  limited  by  their  lack  of  precision.  Moreover,  they  also 
evidence  an  overlap  between  the  values  recorded  in  cases  of 
GRTH and PRTH
11). No differences in the absolute levels of TSH 
or  free  thyroid  hormone  are  observed  in  GRTH  patients  as 
opposed to PRTH patients. Stimulatory and inhibitory tests have 
also  been  conducted  in  GRTH  and  PRTH  patients,  in  order  to 
evaluate the pituitary-thyroid axis in a dynamic manner. The TSH 
r e s p o n s e  t o  T R H  i s  n o r m a l ,  o r  e v e n  e x a g g e r a t e d ,  a n d  i s  
prolonged  in  all  GRTH  and  PRTH  patients
2).  A  molecular 
mechanism to explain these two clinical phenotypes has proven 
elusive, and many authors have concluded that they are part of 
a  spectrum  of  the  same  disorder
13).
TRs  belong  to  the  superfamily  of  ligand-dependent 
transcription  factors.  TRs  are  encoded  by  the  thyroid  hormone 
receptor  α  gene  (THRA)  and  the  thyroid  hormone  receptor  β 
gene  (THRB),  which  are  located  on  chromosomes  17  and  3, 
respectively.  The  expression  of  TRs  occurs  in  a  tissue- 
dependent fashion. Although THRA1 and THRB1 are expressed 
ubiquitously,  THRA1  is  expressed  predominantly  in  the  heart, 
bone, and brain, whereas TRβ1 is expressed more abundantly 
i n t he l i ver,  ki dney,  and t hyroi d.  THRB2 expr essi on i s  l i mi t ed to 
the  pituitary  gland,  hypothalamus,  retina,  and  inner  ear,  and The  Korean  Journal  of  Internal  Medicine  :  Vol.  23,  No.  1,  March  2008 48
Figure  3.  The  sequence  analysis  of  the  thyroid  hormone  receptor  β
gene  (THRB)  in  the  patient.  Automated  direct  sequencing  of  exon 1 1  
reveals  a  heterozygous  G  for  A  substitution  (arrow),  resulting  in  a 
Val349Met  missense  mutation  (c.1045G>A;  p.Val  349Met).
THRB3  expression  occurs  principally  in  the  heart  and  kidney
14). 
One of the most salient reasons for recognizing RTH is that its 
management differs from that of other common forms of thyroid 
dysfunction. In addition, discrimination between GRTH and PRTH 
using  clinical  criteria  remains  useful,  as  the  management  of  the 
two  states  differs.  Patients  with  unequivocal  peripheral  or 
pituitary resistance should not be treated with antithyroid agents, 
as  any  reduction  in  elevated  thyroid  hormones  may  aggravate 
symptoms,  reduce  growth  and  development,  and  exacerbate 
goiter.  Patients  who  present  with  apparent  selective  pituitary 
resistance are the most difficult to manage. Many of the patients 
with  peripheral  resistance  appear  to  benefit  from  further 
increases  in  serum  thyroid  hormone  levels  as  the  result  of 
cautious  exogenous  administration  of  T4 o r  T 3.  At  a  minimum, 
s u c h  t h e r a p y  t e n d s  t o  r e d u c e  s e r u m  T S H  l e v e l s  a n d  g o i t e r  t o  
some  degree
15).
With  the  increasing  availability  of  sensitive  and  specific  TSH 
radioimmunoassys, a greater number of these patients are being 
detected.  It  is  important  to  remember  that  these  patients  may 
display only minimal elevation of serum TSH. On rare occasions, 
TSH  may  be  within  normal  ranges,  but  may  still  be 
inappropriately high, despite elevated free thyroid hormone levels. 
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